Should I buy or sell Affimed stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AFMD shares. View AFMD analyst ratings or view top-rated stocks .

What is Affimed's stock price target for 2024?

5 brokerages have issued 1-year price targets for Affimed's stock. Their AFMD share price targets range from $10.00 to $70.00. On average, they anticipate the company's stock price to reach $45.00 in the next year. This suggests a possible upside of 787.6% from the stock's current price. View analysts price targets for AFMD or view top-rated stocks among Wall Street analysts .

How have AFMD shares performed in 2024?

Affimed's stock was trading at $6.25 on January 1st, 2024. Since then, AFMD shares have decreased by 18.9% and is now trading at $5.07. View the best growth stocks for 2024 here .

Are investors shorting Affimed?

Affimed saw a increase in short interest in March. As of March 31st, there was short interest totaling 196,400 shares, an increase of 14.5% from the March 15th total of 171,600 shares. Based on an average daily volume of 98,300 shares, the short-interest ratio is presently 2.0 days. Approximately 1.5% of the shares of the stock are short sold. View Affimed's Short Interest .

When is Affimed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 28th 2024. View our AFMD earnings forecast .

How were Affimed's earnings last quarter?

Affimed (NASDAQ:AFMD) announced its quarterly earnings data on Wednesday, November, 10th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by $0.10. The biopharmaceutical company earned $10.21 million during the quarter, compared to analyst estimates of $11.79 million. Affimed had a negative net margin of 1,280.27% and a negative trailing twelve-month return on equity of 118.17%. During the same quarter in the prior year, the business posted ($0.80) earnings per share.

When did Affimed's stock split?

Affimed shares reverse split on Monday, March 11th 2024. The 1-10 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Affimed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Affimed investors own include Novavax (NVAX) , JetBlue Airways (JBLU) , SentinelOne (S) , American International Group (AIG) , Sorrento Therapeutics (SRNE) , Catalyst Pharmaceuticals (CPRX) , Amarin (AMRN) , Rigel Pharmaceuticals (RIGL) , Viking Therapeutics (VKTX) and Lipocine (LPCN) .

Who are Affimed's major shareholders?

Affimed's stock is owned by many different institutional and retail investors. Top institutional shareholders include Harbor Investment Advisory LLC (0.04%).

How do I buy shares of Affimed?

Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AFMD

Affimed (AFMD) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free AFMD Stock Alerts

$5.03

-0.04 (-0.79%)

(As of 01:27 PM ET)

Compare

Today's Range: $5.00
▼
$5.21
50-Day Range: $0.61
▼
$6.90
52-Week Range: $2.23
▼
$11.10

Volume: 54,090 shs
Average Volume: 97,429 shs
Market Capitalization: $76.61 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $45.00

Get Affimed alerts:

Affimed MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 787.6% Upside
$45.00 Price Target
Short Interest: Healthy
1.51% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.95
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.53) to ($3.97) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.59 out of 5 stars

Medical Sector

248th out of 918 stocks

Pharmaceutical Preparations Industry

101st out of 424 stocks

3.5

Analyst's Opinion

Consensus Rating
Affimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Affimed has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.51% of the float of Affimed has been sold short.
Short Interest Ratio / Days to Cover
Affimed has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Affimed has recently increased by 14.45%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Affimed does not currently pay a dividend.
Dividend Growth
Affimed does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Affimed has received a 62.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Cancer medication (L01)" product. See details.
Environmental Sustainability
The Environmental Impact score for Affimed is -1.95.

1.9

News and Social Media Coverage

News Sentiment
Affimed has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Affimed this week, compared to 2 articles on an average week.
Search Interest
14 people have searched for AFMD on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Affimed to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Affimed insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.80% of the stock of Affimed is held by insiders.
Percentage Held by Institutions
Only 30.82% of the stock of Affimed is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Affimed are expected to grow in the coming year, from ($4.53) to ($3.97) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Affimed is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Affimed is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Affimed has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Affimed Stock (NASDAQ:AFMD)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

AFMD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AFMD Stock News Headlines

April 14, 2024 | americanbankingnews.com

Affimed (NASDAQ:AFMD) Sees Large Increase in Short Interest

April 11, 2024 | americanbankingnews.com

Affimed (NASDAQ:AFMD) Receives Consensus Rating of "Buy" from Analysts

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 1, 2024 | markets.businessinsider.com

Promising Clinical Trials and Strategic Financial Management Affirm Buy Rating for Affimed

April 1, 2024 | finance.yahoo.com

Affimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call Transcript

March 31, 2024 | markets.businessinsider.com

Buy Rating Affirmed on Affimed: Promising Clinical Outlook and Robust Financial Position

March 31, 2024 | gurufocus.com

Q4 2023 Affimed NV Earnings Call Transcript

March 28, 2024 | markets.businessinsider.com

Here's what Wall Street expects from Affimed's earnings

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 28, 2024 | investorplace.com

AFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q4 2023

March 28, 2024 | globenewswire.com

Affimed Reports 2023 Financial Results and Operational Progress

March 27, 2024 | benzinga.com

A Preview Of Affimed's Earnings

March 21, 2024 | globenewswire.com

Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024

March 13, 2024 | seekingalpha.com

Jefferies starts Cue at buy, cites partnering potential

March 8, 2024 | msn.com

Why Is Affimed (AFMD) Stock Moving Today?

March 8, 2024 | investorplace.com

Why Is Affimed (AFMD) Stock Moving Today?

March 7, 2024 | msn.com

Vaxxinity gains after early-stage data for Parkinson’s disease drug

March 6, 2024 | finanznachrichten.de

Affimed N.V.: Affimed Announces 1-for-10 Reverse Stock Split

March 6, 2024 | msn.com

Affimed falls on 1-for-10 reverse stock split

March 6, 2024 | investorplace.com

7 of the Best Speculative Stocks You Can Snag for Less Than $1

March 6, 2024 | globenewswire.com

Affimed Announces 1-for-10 Reverse Stock Split

January 9, 2024 | marketwatch.com

Affimed CEO Adi Hoess Steps Down; Co to Cut Up to 50% of Workforce

January 9, 2024 | finanznachrichten.de

Affimed N.V.: Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer

January 8, 2024 | marketwatch.com

Affimed N.V. to Expand Cohort in Study of AFM24 Following Promising Data

January 8, 2024 | finance.yahoo.com

Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer

January 8, 2024 | finance.yahoo.com

Affimed Announces Leadership Change and Organizational Restructuring

January 3, 2024 | finanznachrichten.de

Affimed N.V.: Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck

See More Headlines

Receive AFMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/28/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:AFMD
CUSIP: N/A
CIK: 1608390
Web: www.affimed.com
Phone: 496221674360
Fax: 49-6221-653-0777
Employees: 219
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $45.00
High Stock Price Target: $70.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +787.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($8.40)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-114,660,000.00
Net Margins: -1,280.27%
Pretax Margin: -1,280.19%
Return on Equity: -118.17%
Return on Assets: -81.35%

Debt

Debt-to-Equity Ratio: 0.11
Current Ratio: 3.25
Quick Ratio: 3.23

Sales & Book Value

Annual Sales: $8.95 million
Price / Sales: 8.63
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.19 per share
Price / Book: 1.21

Miscellaneous

Outstanding Shares: 15,230,000
Free Float: 14,648,000
Market Cap: $77.22 million
Optionable: Optionable
Beta: 2.05

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Andreas Harstrick M.D. (Age 63)
Interim CEO, Chief Medical Officer & Member of Management Board
Comp: $535.09k
Dr. Wolfgang Fischer (Age 60)
MD, COO & Member of Management Board
Comp: $645.58k
Ms. Denise Mueller (Age 54)
Chief Business Officer & Member of Management Board
Comp: $628.24k
Prof. Melvyn Little
Founder & Consultant
Mr. Michael Wolf (Age 57)
Head of Finance & Administration
Mr. Alexander Fudukidis
Head of Investor Relations & Director of Investor Relations
Mary Beth Sandin
Vice President of Marketing & Communications

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

AFMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Affimed stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AFMD shares.
View AFMD analyst ratings or view top-rated stocks.
What is Affimed's stock price target for 2024?: 5 brokerages have issued 1-year price targets for Affimed's stock. Their AFMD share price targets range from $10.00 to $70.00. On average, they anticipate the company's stock price to reach $45.00 in the next year. This suggests a possible upside of 787.6% from the stock's current price.
View analysts price targets for AFMD or view top-rated stocks among Wall Street analysts.
How have AFMD shares performed in 2024?: Affimed's stock was trading at $6.25 on January 1st, 2024. Since then, AFMD shares have decreased by 18.9% and is now trading at $5.07.
View the best growth stocks for 2024 here.
Are investors shorting Affimed?: Affimed saw a increase in short interest in March. As of March 31st, there was short interest totaling 196,400 shares, an increase of 14.5% from the March 15th total of 171,600 shares. Based on an average daily volume of 98,300 shares, the short-interest ratio is presently 2.0 days. Approximately 1.5% of the shares of the stock are short sold.
View Affimed's Short Interest.
When is Affimed's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 28th 2024.
View our AFMD earnings forecast.
How were Affimed's earnings last quarter?: Affimed (NASDAQ:AFMD) announced its quarterly earnings data on Wednesday, November, 10th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by $0.10. The biopharmaceutical company earned $10.21 million during the quarter, compared to analyst estimates of $11.79 million. Affimed had a negative net margin of 1,280.27% and a negative trailing twelve-month return on equity of 118.17%. During the same quarter in the prior year, the business posted ($0.80) earnings per share.

When did Affimed's stock split?: Affimed shares reverse split on Monday, March 11th 2024. The 1-10 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of Affimed own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Affimed investors own include Novavax (NVAX), JetBlue Airways (JBLU), SentinelOne (S), American International Group (AIG), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Amarin (AMRN), Rigel Pharmaceuticals (RIGL), Viking Therapeutics (VKTX) and Lipocine (LPCN).
Who are Affimed's major shareholders?: Affimed's stock is owned by many different institutional and retail investors. Top institutional shareholders include Harbor Investment Advisory LLC (0.04%).
How do I buy shares of Affimed?: Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AFMD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Affimed (AFMD) Stock Price, News & Analysis

Affimed MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Affimed Stock (NASDAQ:AFMD)

AFMD Stock Price History

AFMD Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

AFMD Stock Analysis - Frequently Asked Questions

Overall MarketRank^™